Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil

Latin American Cooperative Oncology Group403 enrolled

Overview

RELANCE is a large multi-institutional study that aims to retrospectively collect information about diagnostic, treatment and outcome of patients diagnosed with locally advanced NSCLC in Brazil. It is hypothesized that there is a great heterogeneity in treatment patterns owing to inequities in access to adequate staging methods, optimal treatment and multidisciplinary teams in Brazil.

RELANCE study will collect sociodemographic and clinical data of patients diagnosed with locally advanced NSCLC in the period of January 2015 and Jun 2019 in the participating institutions. Socio-demographic characteristics, clinicopathological features, treatments patterns and outcomes will be recovered from medical charts. Disease status and survival data will be collected up to the last date of follow-up June 2021.

Study Type

OBSERVATIONAL

Enrollment

403

Conditions

Lung Cancer, Non-small Cell

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients aged 18 years or older; 2. Histologically or cytological diagnosis of NSCLC in the period of January 2015 to December 2016; 3. Locally Advanced NSCLC defined as clinical stage IIIA and IIIB according to 7th Edition TNM Staging System; 4. Any NSCLC histological subtype and molecular mutation; 5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis; 6. Patients assigned by treating physician to any therapy or palliative care; 7. Access to patient medical chart for data collection. Exclusion Criteria: 1. Small cell lung cancer and non-invasive NSCLC; 2. Synchronic NSCLC or second primary tumour in the last 5 years (except non-melanoma skin cancer).

Locations (1)

AC Camargo

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

Overall survival

defined as time from diagnosis to death of any cause;

Time frame: Up to June 30, 2018

Secondary Outcomes

Progression free survival

defined as time from any line of treatment to progression of the disease or death of any cause

Time frame: Up to June 30, 2018

Time to next treatment

defined as time from start of the any treatment to the beginning of a second therapy

Time frame: Up to June 30, 2018

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.